Breaking Finance News

Rockwell Medical Inc (NASDAQ:RMTI) price target bumped up to $12.00, reported earlier today by BTIG Research

BTIG Research bumped the target price of Rockwell Medical Inc (NASDAQ:RMTI) to $12, stating a possible upside of 0.66%.

Showing a price of $7.22, Rockwell Medical Inc (NASDAQ:RMTI) traded 0.87% lower on the day. With the last stock price close down 12.20% from the 200-day moving average, compared to the S&P 500 which has fallen -0.01% over the same period. RMTI has recorded a 50-day average of $7.38 and two hundred day moving average of $7.80. 354,134 shares of the stock traded hands, up from ann average trading volume of 322,253

See Graph Below:

Rockwell Medical Inc (NASDAQ:RMTI)

With a market cap of $0.0, Rockwell Medical Inc has a 52 week low of $5.47 and a one-year high of $13.50 with a P/E ratio of 0.

General Company Details For Rockwell Medical Inc (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, and along with a range of ancillary products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *